Cargando…
IMMU-04. TARGETING ALTERNATIVE SPLICING VARIANTS TO STIMULATE ANTI-TUMOR IMMUNITY IN A NOVEL SYNGENEIC MOUSE MODEL OF DIFFUSE HEMISPHERIC GLIOMA, H3 G34-MUTANT
Juvenile presentation of HGG has been shown to frequently involve somatic mutations of the H3-3A gene, which encodes a histone H3 variant. To address the paucity of identified TSAs in DHG, we utilized a novel computational platform, Isoform peptides from RNA splicing for Immunotherapy target Screeni...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10259920/ http://dx.doi.org/10.1093/neuonc/noad073.191 |
_version_ | 1785057745714544640 |
---|---|
author | Owens, Geoffrey Pan, Yang Treger, Janet Contreras, Erick Soto, Horacio Armellini, Amber Na, Brian Liau, Linda Prins, Robert Xing, Yi Wang, Anthony |
author_facet | Owens, Geoffrey Pan, Yang Treger, Janet Contreras, Erick Soto, Horacio Armellini, Amber Na, Brian Liau, Linda Prins, Robert Xing, Yi Wang, Anthony |
author_sort | Owens, Geoffrey |
collection | PubMed |
description | Juvenile presentation of HGG has been shown to frequently involve somatic mutations of the H3-3A gene, which encodes a histone H3 variant. To address the paucity of identified TSAs in DHG, we utilized a novel computational platform, Isoform peptides from RNA splicing for Immunotherapy target Screening (IRIS). The IRIS pipeline is designed to leverage large-scale cancer and normal transcriptomic data to identify peptide sequences that result from alternative splicing events that are highly enriched in cancer cells, and are predicted to bind the HLA class I alleles carried by the individual patient. To investigate whether peptide-pulsed dendritic cells (DC) together with checkpoint blockade might be a potential treatment modality for diffuse hemispheric glioma, H3 G34-mutant, we have developed a novel mouse model, and utilized a novel bioinformatics pipeline to identify tumor-associated peptide antigens. We used the RCAS/tv-A system to target the expression of H3/G34R and PDGF-B and to knock out p53 in neural progenitors in transgenic C57BL/6 neonatal mice. Three independent cell lines were obtained that expressed transcripts associated with oligodendrocyte and interneuron lineages, and formed lethal tumors after intracranial implantation. Implementing IRIS, we identified nonapeptides generated from alternative splicing of mRNAs that were highly enriched in the tumor transcriptomes of two H3/G34R patients, and predicted to bind the HLA-A*2:01 class I allele carried by these patients. Three of the candidate peptides were conserved in the mouse and also predicted to bind the H2-Kb MHC I allele carried by C57/BL6 mice. Using our syngeneic mouse model, we showed that DCs pulsed with these peptides together with anti-PD1 mAb provided a significant survival benefit compared with checkpoint inhibitor and DCs pulsed with peptides that were not predicted to bind the H2-Kb allele. |
format | Online Article Text |
id | pubmed-10259920 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-102599202023-06-13 IMMU-04. TARGETING ALTERNATIVE SPLICING VARIANTS TO STIMULATE ANTI-TUMOR IMMUNITY IN A NOVEL SYNGENEIC MOUSE MODEL OF DIFFUSE HEMISPHERIC GLIOMA, H3 G34-MUTANT Owens, Geoffrey Pan, Yang Treger, Janet Contreras, Erick Soto, Horacio Armellini, Amber Na, Brian Liau, Linda Prins, Robert Xing, Yi Wang, Anthony Neuro Oncol Final Category: Immunology/Immunotherapy - IMMU Juvenile presentation of HGG has been shown to frequently involve somatic mutations of the H3-3A gene, which encodes a histone H3 variant. To address the paucity of identified TSAs in DHG, we utilized a novel computational platform, Isoform peptides from RNA splicing for Immunotherapy target Screening (IRIS). The IRIS pipeline is designed to leverage large-scale cancer and normal transcriptomic data to identify peptide sequences that result from alternative splicing events that are highly enriched in cancer cells, and are predicted to bind the HLA class I alleles carried by the individual patient. To investigate whether peptide-pulsed dendritic cells (DC) together with checkpoint blockade might be a potential treatment modality for diffuse hemispheric glioma, H3 G34-mutant, we have developed a novel mouse model, and utilized a novel bioinformatics pipeline to identify tumor-associated peptide antigens. We used the RCAS/tv-A system to target the expression of H3/G34R and PDGF-B and to knock out p53 in neural progenitors in transgenic C57BL/6 neonatal mice. Three independent cell lines were obtained that expressed transcripts associated with oligodendrocyte and interneuron lineages, and formed lethal tumors after intracranial implantation. Implementing IRIS, we identified nonapeptides generated from alternative splicing of mRNAs that were highly enriched in the tumor transcriptomes of two H3/G34R patients, and predicted to bind the HLA-A*2:01 class I allele carried by these patients. Three of the candidate peptides were conserved in the mouse and also predicted to bind the H2-Kb MHC I allele carried by C57/BL6 mice. Using our syngeneic mouse model, we showed that DCs pulsed with these peptides together with anti-PD1 mAb provided a significant survival benefit compared with checkpoint inhibitor and DCs pulsed with peptides that were not predicted to bind the H2-Kb allele. Oxford University Press 2023-06-12 /pmc/articles/PMC10259920/ http://dx.doi.org/10.1093/neuonc/noad073.191 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Final Category: Immunology/Immunotherapy - IMMU Owens, Geoffrey Pan, Yang Treger, Janet Contreras, Erick Soto, Horacio Armellini, Amber Na, Brian Liau, Linda Prins, Robert Xing, Yi Wang, Anthony IMMU-04. TARGETING ALTERNATIVE SPLICING VARIANTS TO STIMULATE ANTI-TUMOR IMMUNITY IN A NOVEL SYNGENEIC MOUSE MODEL OF DIFFUSE HEMISPHERIC GLIOMA, H3 G34-MUTANT |
title | IMMU-04. TARGETING ALTERNATIVE SPLICING VARIANTS TO STIMULATE ANTI-TUMOR IMMUNITY IN A NOVEL SYNGENEIC MOUSE MODEL OF DIFFUSE HEMISPHERIC GLIOMA, H3 G34-MUTANT |
title_full | IMMU-04. TARGETING ALTERNATIVE SPLICING VARIANTS TO STIMULATE ANTI-TUMOR IMMUNITY IN A NOVEL SYNGENEIC MOUSE MODEL OF DIFFUSE HEMISPHERIC GLIOMA, H3 G34-MUTANT |
title_fullStr | IMMU-04. TARGETING ALTERNATIVE SPLICING VARIANTS TO STIMULATE ANTI-TUMOR IMMUNITY IN A NOVEL SYNGENEIC MOUSE MODEL OF DIFFUSE HEMISPHERIC GLIOMA, H3 G34-MUTANT |
title_full_unstemmed | IMMU-04. TARGETING ALTERNATIVE SPLICING VARIANTS TO STIMULATE ANTI-TUMOR IMMUNITY IN A NOVEL SYNGENEIC MOUSE MODEL OF DIFFUSE HEMISPHERIC GLIOMA, H3 G34-MUTANT |
title_short | IMMU-04. TARGETING ALTERNATIVE SPLICING VARIANTS TO STIMULATE ANTI-TUMOR IMMUNITY IN A NOVEL SYNGENEIC MOUSE MODEL OF DIFFUSE HEMISPHERIC GLIOMA, H3 G34-MUTANT |
title_sort | immu-04. targeting alternative splicing variants to stimulate anti-tumor immunity in a novel syngeneic mouse model of diffuse hemispheric glioma, h3 g34-mutant |
topic | Final Category: Immunology/Immunotherapy - IMMU |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10259920/ http://dx.doi.org/10.1093/neuonc/noad073.191 |
work_keys_str_mv | AT owensgeoffrey immu04targetingalternativesplicingvariantstostimulateantitumorimmunityinanovelsyngeneicmousemodelofdiffusehemisphericgliomah3g34mutant AT panyang immu04targetingalternativesplicingvariantstostimulateantitumorimmunityinanovelsyngeneicmousemodelofdiffusehemisphericgliomah3g34mutant AT tregerjanet immu04targetingalternativesplicingvariantstostimulateantitumorimmunityinanovelsyngeneicmousemodelofdiffusehemisphericgliomah3g34mutant AT contreraserick immu04targetingalternativesplicingvariantstostimulateantitumorimmunityinanovelsyngeneicmousemodelofdiffusehemisphericgliomah3g34mutant AT sotohoracio immu04targetingalternativesplicingvariantstostimulateantitumorimmunityinanovelsyngeneicmousemodelofdiffusehemisphericgliomah3g34mutant AT armelliniamber immu04targetingalternativesplicingvariantstostimulateantitumorimmunityinanovelsyngeneicmousemodelofdiffusehemisphericgliomah3g34mutant AT nabrian immu04targetingalternativesplicingvariantstostimulateantitumorimmunityinanovelsyngeneicmousemodelofdiffusehemisphericgliomah3g34mutant AT liaulinda immu04targetingalternativesplicingvariantstostimulateantitumorimmunityinanovelsyngeneicmousemodelofdiffusehemisphericgliomah3g34mutant AT prinsrobert immu04targetingalternativesplicingvariantstostimulateantitumorimmunityinanovelsyngeneicmousemodelofdiffusehemisphericgliomah3g34mutant AT xingyi immu04targetingalternativesplicingvariantstostimulateantitumorimmunityinanovelsyngeneicmousemodelofdiffusehemisphericgliomah3g34mutant AT wanganthony immu04targetingalternativesplicingvariantstostimulateantitumorimmunityinanovelsyngeneicmousemodelofdiffusehemisphericgliomah3g34mutant |